VANCOUVER, British Columbia, Canada — March 18, 2026 — Integrated Nanotherapeutics (INT), a biotechnology company developing next-generation lipid nanoparticle (LNP) therapeutics for immune-mediated diseases, today announced that it has been awarded funding through the Genome Canada Genomic Applications Partnership Program (GAPP), with support from Genome British Columbia, to advance its multi-cargo mRNA/LNP therapy for type 1 diabetes (T1D).
The project will be conducted in collaboration with researchers at the University of British Columbia and the Advanced Therapeutics Manufacturing Facility (ATMF), where manufacturing development and scale-up of the therapy will be carried out to support future clinical studies.
INT’s therapeutic candidate, INT-101, is based on the company’s proprietary multi-cargo lipid nanoparticle platform, which enables the co-delivery of mRNA encoding beta-cell antigens and small-molecule immunomodulators in a single nanoparticle to restore immune tolerance. The approach aims to halt the autoimmune destruction of insulin-producing beta cells that drives T1D.
Preclinical studies have demonstrated compelling proof-of-concept in animal models of T1D, including reversal of disease in animals with new-onset diabetes.
“This award from Genome Canada and Genome BC provides important support to advance our immune-tolerance platform toward the clinic,” said Dr. Chris Tam, Co-Founder and Chief Executive Officer of Integrated Nanotherapeutics. “By combining our multi-cargo LNP technology with the advanced manufacturing capabilities at UBC’s ATMF, we aim to accelerate development of a disease-modifying therapy for people living with T1D.”
The project will scale manufacturing of the therapy at ATMF, validate the therapeutic mRNA using samples from individuals with type 1 diabetes, and prepare a clinical trial application to Health Canada to support future clinical studies.
“ATMF was established to enable Canadian innovators to translate advanced therapeutics from discovery to the clinic,” said Dr. Megan Levings, Professor at the University of British Columbia and scientific lead of the project. “This collaboration brings together academic and industry expertise to accelerate the development of new approaches for treating T1D as well as other autoimmune diseases.”
Type 1 diabetes affects more than 9 million people worldwide and currently requires lifelong insulin therapy. Despite advances in glucose monitoring and insulin delivery, available treatments do not address the underlying autoimmune cause of the disease.
INT’s multi-cargo mRNA/LNP platform is designed to enable antigen-specific immune tolerance therapies for multiple autoimmune diseases. Completion of the project is expected to advance INT’s clinical readiness while strengthening Canada’s ecosystem for the development and manufacturing of complex mRNA/LNP therapeutics.
About Integrated Nanotherapeutics (INT)
Integrated Nanotherapeutics is a biotechnology company developing next-generation lipid nanoparticle therapeutics for autoimmune diseases. The company’s proprietary multi-cargo LNP platform enables the co-delivery of mRNA and small-molecule immunomodulators to induce antigen-specific immune tolerance. INT’s lead program targets type 1 diabetes. The company is headquartered in Vancouver, Canada. For more information, visit www.integratedntx.com